Cite
HARVARD Citation
Devillier, R. et al. (n.d.). Comparison of 60 or 90 mg/m2 of daunorubicin in induction therapy for acute myeloid leukemia with intermediate or unfavorable cytogenetics. American journal of hematology. 90 (2), pp. E29-E30. [Online].